ECM23 Antibody

What is CD23 and why is it an important target for antibody-based research?

CD23 is a 45 kDa type II transmembrane glycoprotein that functions as a low-affinity receptor for IgE. It is expressed on mature B cells, mantle zone B cells, follicular dendritic cells, and at lower levels on T cells, NK cells, Langerhans cells, and platelets . CD23 plays a critical role in the regulation of IgE production and allergy-induced immune and inflammatory responses . As a key molecule in B cell growth and differentiation, CD23 also exists in soluble forms that act as potent mitogenic factors . These characteristics make CD23 an important target for studying allergic diseases, B cell function, and potential therapeutic interventions.

What are the primary applications of CD23 antibodies in research settings?

CD23 antibodies are primarily used in several experimental applications:

• Flow cytometry: CD23 antibodies are extensively used for detecting CD23 expression on human blood lymphocytes, particularly B cells. The antibodies can be used in multicolor flow cytometry panels alongside other markers like CD19 for comprehensive immunophenotyping .

• Immunohistochemistry (IHC): CD23 antibodies can be used to detect CD23 expression in fixed tissues such as lymph nodes, where specific staining is localized to cell membranes in lymphocytes .

• Functional studies: Anti-CD23 antibodies like lumiliximab are used to investigate immune regulation mechanisms, including their effects on allergen-induced immune responses .

• Cell activation studies: Since CD23 expression is upregulated upon B cell activation, these antibodies serve as valuable tools for monitoring B cell stimulation .

How do I select the appropriate CD23 antibody clone for my specific application?

Selecting the appropriate CD23 antibody clone requires consideration of several factors:

• Epitope recognition: Different clones recognize different epitopes of CD23. For example, clone 138628 recognizes the Met150-Ser321 region of human CD23 , while other clones may target different regions.

• Application compatibility: Confirm the antibody has been validated for your specific application. For instance, the EBVCS2 clone has been pre-titrated and tested for flow cytometric analysis of human peripheral blood cells .

• Species reactivity: Ensure the antibody reacts with your species of interest. Most commercial CD23 antibodies are specific for human CD23.

• Conjugation needs: Consider whether you need a conjugated antibody (e.g., APC-conjugated) for direct detection or an unconjugated antibody for flexibility in experimental design .

• Published validation data: Review vendor data sheets and independent literature validating the antibody's specificity and performance in applications similar to yours .

It is advisable to consult multiple sources of information, including vendor specifications, published literature, and public antibody validation databases before making a selection .

How can I optimize flow cytometry protocols when using CD23 antibodies for B cell phenotyping?

Optimizing flow cytometry protocols with CD23 antibodies requires attention to several methodological details:

• Antibody titration: Although pre-titrated antibodies like EBVCS2 can be used at recommended concentrations (5 μL or 0.125 μg per test for 10^5 to 10^8 cells), optimal dilutions should be determined empirically for each laboratory and application .

• Panel design: When designing multicolor panels, pair CD23 antibodies with B cell markers like CD19. In studies, human peripheral blood lymphocytes have been effectively stained with Mouse Anti-Human CD19 APC-conjugated Monoclonal Antibody and Mouse Anti-Human CD23/Fc epsilon RII Monoclonal Antibody .

• Appropriate controls: Include isotype controls such as Mouse IgG1 Isotype Control followed by appropriate secondary antibodies (e.g., Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody) .

• Sample preparation: Fresh peripheral blood samples yield optimal results. If using frozen samples, ensure proper thawing and recovery protocols.

• Gating strategy: First gate on lymphocytes based on FSC/SSC properties, then identify B cells using CD19 before analyzing CD23 expression.

• Fluorophore selection: Consider the excitation and emission properties of your fluorophores. For example, APC-conjugated antibodies work with red lasers (Excitation: 633-647 nm; Emission: 660 nm) .

What considerations are important when using CD23 antibodies in immunohistochemistry studies?

When using CD23 antibodies for immunohistochemistry, researchers should consider:

• Tissue preparation: CD23 antibodies have been successfully used on immersion-fixed paraffin-embedded sections of human lymph nodes .

• Epitope retrieval: Heat-induced epitope retrieval is crucial for optimal staining. Using appropriate antigen retrieval reagents (e.g., VisUCyte Antigen Retrieval Reagent-Basic) is recommended before incubation with the primary antibody .

• Antibody concentration: Optimal concentration should be determined empirically, though 5 μg/mL for 1 hour at room temperature has been effective with Mouse Anti-Human CD23/Fc epsilon RII Monoclonal Antibody (MAB123) .

• Detection system: Secondary antibody selection is critical. Anti-Goat IgG VisUCyte HRP Polymer Antibody has been used successfully in conjunction with DAB (brown) staining and hematoxylin (blue) counterstaining .

• Specificity controls: Include appropriate negative controls by omitting primary antibody or using isotype-matched control antibodies.

• Expected staining pattern: Specific CD23 staining should be localized to cell membranes in lymphocytes, particularly in regions containing B cells .

How can anti-CD23 antibodies be used to study allergen-induced immune responses?

Anti-CD23 antibodies like lumiliximab have been utilized to investigate allergen-induced immune responses through several methodological approaches:

• PBMC stimulation assays: Peripheral blood mononuclear cells (PBMCs) from atopic subjects can be pre-treated with anti-CD23 antibodies (like lumiliximab) before allergen stimulation to assess their effects on immune responses .

• Proliferation assessment: Cell proliferation can be measured to evaluate the immunomodulatory effects of anti-CD23 antibodies. Research has shown that lumiliximab reduced allergen-induced PBMC proliferation by approximately 50% (P = 0.006) .

• Cytokine profiling: Culture supernatants can be analyzed for cytokine production. Lumiliximab treatment has been shown to reduce proinflammatory cytokines IL-1β (P < 0.003) and TNF-α (P = 0.05), as well as the TH2 cytokine IL-5 (P = 0.002) .

• Comparative studies: The effects of anti-CD23 antibodies can be compared with other immunomodulatory approaches, such as blocking HLA-DR and costimulatory molecules (CD80 and CD86) .

• T-cell line experiments: Allergen-specific T-cell lines can be developed to analyze lymphocyte proliferation in response to allergen with or without anti-CD23 antibody treatment .

• Analysis of costimulatory molecule expression: Flow cytometry can be used to evaluate the effect of anti-CD23 antibodies on the expression of costimulatory molecules like CD86 .

What mechanisms underlie the immunomodulatory effects of anti-CD23 antibodies?

Anti-CD23 antibodies exert their immunomodulatory effects through several molecular mechanisms:

• Disruption of IgE regulation: CD23 is a low-affinity receptor for IgE and plays a role in IgE production. Anti-CD23 antibodies can interfere with this process, potentially affecting allergic responses .

• Modulation of antigen-presenting cells: Research indicates that anti-CD23 antibodies like lumiliximab may modulate antigen-presenting cell function, thereby influencing T-cell activation and subsequent immune responses .

• Reduction of costimulatory molecule expression: Lumiliximab has been shown to reduce surface expression of CD86 on cytokine-stimulated U937 monocytic cells (P = 0.012), potentially affecting T-cell activation .

• Inhibition of TH2-type immune responses: By reducing IL-5 production, anti-CD23 antibodies may specifically inhibit TH2-type responses that are characteristic of allergic reactions .

• Interference with CD23-ligand interactions: CD23 binds to several ligands including CD21, IgE, CD11b, and CD11c. Anti-CD23 antibodies may block these interactions, affecting various immune pathways .

• Regulation of soluble CD23: Anti-CD23 antibodies might affect the generation or function of soluble CD23 forms, which show distinct bioactivities compared to membrane-bound CD23 .

How can I address potential cross-reactivity issues when using CD23 antibodies?

Cross-reactivity is a common challenge when working with antibodies. To address this issue with CD23 antibodies:

• Antibody validation: Before proceeding with experiments, validate the specificity of your CD23 antibody using positive and negative control samples. Cells known to express high levels of CD23 (e.g., EBV-transformed B lymphoblasts) can serve as positive controls .

• Isotype controls: Always include appropriate isotype controls in your experiments to distinguish specific from non-specific binding. For instance, Mouse IgG1 Isotype Control (MAB002) can be used alongside Mouse Anti-Human CD23/Fc epsilon RII Monoclonal Antibody .

• Multiple detection methods: Confirm findings using alternative detection methods. If cross-reactivity is observed in flow cytometry, verify with immunohistochemistry or Western blotting.

• Epitope mapping: Consider the specific epitope recognized by your antibody. The clone 138628, for example, recognizes the Met150-Ser321 region of human CD23 .

• Blocking experiments: Perform competitive binding assays using recombinant CD23 to confirm specificity.

• Literature validation: Cross-reference your findings with published literature to ensure consistency with established patterns of CD23 expression and antibody reactivity .

What factors might contribute to inconsistent results when using CD23 antibodies in research?

Inconsistent results with CD23 antibodies can stem from various factors:

• Antibody quality and characterization: Approximately 50% of commercial antibodies fail to meet basic standards for characterization, leading to reproducibility issues . Ensure your antibody has been properly validated.

• Experimental conditions: Variables such as incubation time, temperature, buffer composition, and cell fixation methods can significantly impact antibody performance. For instance, for IHC with MAB123, specific conditions (5 μg/mL for 1 hour at room temperature) have been recommended .

• Sample preparation: Variations in sample processing can affect CD23 detection. Fresh samples typically yield more consistent results than frozen or improperly stored samples.

• Expression dynamics: CD23 expression is upregulated upon B cell activation, meaning the activation state of your cells can influence detection levels .

• Isoform specificity: CD23 exists in multiple isoforms and soluble forms, and different antibodies may have different specificities for these variants .

• Protocol standardization: Lack of standardized protocols across laboratories contributes to variability. Follow established protocols for your specific application and antibody clone .

• Lot-to-lot variability: Different production lots of the same antibody may show performance variations. When possible, use the same lot for related experiments or validate new lots against previous ones.

How can CD23 antibodies be used to investigate the relationship between CD23 and other immune molecules?

CD23 antibodies can be powerful tools for investigating complex immune interactions:

• Co-immunoprecipitation studies: CD23 antibodies can be used to pull down CD23 and associated proteins to identify interaction partners.

• Dual-labeling experiments: CD23 antibodies can be combined with antibodies against potential interaction partners (CD21, IgE, CD11b, and CD11c) in flow cytometry or immunofluorescence to study co-localization .

• Functional blockade experiments: CD23 antibodies can be used alongside antibodies against other immune molecules (e.g., CD80, CD86, HLA-DR) to compare their effects on cellular functions like proliferation and cytokine production. Research has shown that blocking CD86 resulted in greater reduction in proliferation than anti-CD23 (lumiliximab), but similar effects on cytokine secretion .

• Signaling pathway analysis: CD23 antibodies can help investigate how CD23 engagement affects downstream signaling pathways, particularly those involved in B cell activation and IgE regulation.

• Study of soluble vs. membrane-bound forms: Different CD23 antibodies may preferentially recognize membrane-bound or soluble forms of CD23, enabling research into their distinct biological functions .

What are the latest research developments in therapeutic applications of anti-CD23 antibodies?

Research on therapeutic applications of anti-CD23 antibodies has shown promising developments:

• Allergic disease treatment: Anti-CD23 antibodies like lumiliximab have demonstrated potential in reducing allergen-induced immune responses, suggesting clinical benefits for treating allergic diseases .

• Safety profile: Lumiliximab has been demonstrated to be safe in human clinical trials, an important milestone for therapeutic antibody development .

• Mechanism of action: Research has elucidated that anti-CD23 antibodies may work by modulating antigen-presenting cells and reducing TH2-type immune responses, providing a mechanistic basis for their therapeutic effects .

• Comparative effectiveness: Studies comparing anti-CD23 antibodies with other immunomodulatory approaches (like blocking costimulatory molecules) have provided insights into their relative efficacy and potential combinatorial strategies .

• Biomarker development: Research with anti-CD23 antibodies has contributed to the identification of potential biomarkers for allergic diseases and treatment response.